Merrimack currently has six oncology therapeutics in clinical development, multiple product candidates in preclinical development and an active Systems Biology-driven discovery effort.
Merrimack is applying its novel diagnostics and therapeutics in the clinic through the development of regimens for specific tumor types. These regimens couple diagnostic and therapeutic combinations that are targeted to improve patient outcomes. Click below to learn more about our regimens.
Browse our library to explore published research papers, clincal data, conference presentations and featured scientific news and events related to Merrimack.
MM-121/SAR256212 is a fully human monocolonal antibody that targets the HER3 receptor. Merrimack’s Network Biology approach identified HER3 as a critical tumorigenic node in several types of cancer.
MM-111 is a first-in-class bispecific antibody that has been shown in preclinical studies to bind with both specificity and avidity to HER2 and HER3 expressing tumor cells. The HER2 arm is responsible for initial tumor cell targeting and docking, while the therapeutic HER3 arm is designed to block heregulin-induced cell signaling.
MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monocolonal antibodies designed to bind and inhibit signaling of the Epidermal Growth Factor Receptor (EGFR).
MM-141 is a monoclonal antibody that acts as a tetravalent inhibitor of PI3K/AKT/mTOR, which is a major pro-survival pathway tumor cells use as a resistance mechanism to anti-cancer therapies.
MM-131 is currently in preclinical development.
MM-302 is a HER2-targeted nanotherapeutic consisting of the chemotherapeutic doxorubicin, encapsulated in a liposomal sphere. Doxorubicin has been a standard therapy for the treatment of breast cancer for more than 30 years.
MM-310 is currently in preclinical development.